Recent Posts
News•Feb 24, 2026
AF Common, Worsens Prognosis After Stem Cell Transplant for Multiple Myeloma
A retrospective study of 801 multiple myeloma patients undergoing autologous stem cell transplantation found that 8.7% developed atrial fibrillation post‑procedure. Age over 65, prior paroxysmal AF, and obesity were independent risk factors, with a median onset of 13 days. Post‑transplant AF was associated with a five‑fold rise in all‑cause mortality and a four‑fold increase in non‑relapse mortality. The authors stress mandatory cardiovascular evaluation and ongoing surveillance before, during, and after transplant.
By TCTMD
News•Feb 24, 2026
Holding Out Hope for HF Shunts, Even After an FDA Panel’s Doubts
The FDA Circulatory System Devices Panel rejected the V‑Wave interatrial shunt, citing a neutral primary endpoint in the RELIEVE‑HF trial despite promising subgroup results in HFrEF patients. The trial showed no overall reduction in mortality, hospitalizations, or quality‑of‑life measures, and...
By TCTMD
News•Feb 23, 2026
Worsening CAC Tied to Cognitive Decline in Midlife: CARDIA
A new analysis of the CARDIA cohort shows that progression of coronary artery calcium (CAC) over roughly a decade is linked to measurable declines in processing speed and global cognition among middle‑aged adults. The relationship holds regardless of baseline CAC...
By TCTMD
News•Feb 20, 2026
AI in Cardiovascular Imaging and Interventions: Boon or Bane?
At the 2026 EAPCI Summit, experts highlighted AI’s expanding role in cardiovascular interventions, from mortality risk modeling to intravascular imaging analysis. A University of Galway study identified gamma‑glutamyl transferase as a strong 10‑year mortality predictor in the SYNTAX cohort, validated...
By TCTMD
News•Feb 18, 2026
Transfer Delays Tied to Worse Acute Stroke Intervention Results
A new Lancet Neurology study of 22,410 ischemic‑stroke patients shows that door‑in‑door‑out (DIDO) times exceeding the 90‑minute guideline are tied to poorer functional outcomes and lower rates of endovascular therapy. Patients with DIDO intervals of 91‑180 minutes, 181‑270 minutes, and...
By TCTMD
News•Feb 18, 2026
Rox Heart Radio: Why AI?
Rox Heart Radio released a new episode titled “Why AI?” featuring host Roxana Mehran in conversation with cardiology researchers Ami Bhatt and Rohan Khera. The trio explores how artificial intelligence is poised to reshape cardiovascular care, from imaging interpretation to risk prediction....
By TCTMD
News•Feb 13, 2026
When Nudges Aren’t Enough: Study Ponders AS Referral System Changes
A Canadian study of 343 patients with moderate or severe aortic stenosis found that automated prompts in echocardiography reports and EMRs only modestly improved specialist referrals. About 60% of severe AS patients and just over 20% of moderate cases were...
By TCTMD
News•Feb 13, 2026
Adult Survivors of Childhood Cancer May Do Well With Simple Strategy for CV Risk
A randomized trial of 347 adult survivors of childhood cancer found that early cardiovascular (CV) risk screening alone was as effective as screening plus one‑on‑one counseling. Both groups showed improvements in blood pressure and lipid measures, with the counseling arm...
By TCTMD
News•Feb 12, 2026
Loberamisal Scores a Rare Win for Stroke Neuroprotection
The phase III LAIS trial showed that loberamisal, a novel neuroprotectant, raised the proportion of acute ischemic‑stroke patients achieving an excellent functional outcome (mRS 0‑1) to 69.7% versus 56.4% with placebo when given within 48 hours of symptom onset. The study enrolled 997...
By TCTMD
News•Feb 12, 2026
Pediatric and Congenital Heart Disease Series: Rheumatic Valve Disease
The TCTMD podcast released a new episode in its Pediatric and Congenital Heart Disease series focusing on rheumatic valve disease. Hosts Ami Bhatt and Robert Levine explore the diagnostic hurdles that pediatric patients face, including overlapping symptoms with other cardiac...
By TCTMD
News•Feb 11, 2026
OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke
The randomized OPTION trial showed that intravenous tenecteplase given 4.5 to 24 hours after symptom onset improves functional outcomes in patients with acute non‑large‑vessel‑occlusion (non‑LVO) strokes. At 90 days, 43.6% of tenecteplase recipients achieved a modified Rankin Scale score of...
By TCTMD